Novartis AG PE Ratio 2010-2022 | NVS

Current and historical p/e ratio for Novartis AG (NVS) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of June 23, 2022 is 13.18.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Novartis AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-06-23 81.86 7.62
2022-03-31 87.75 $10.74 8.17
2021-12-31 83.95 $10.65 7.88
2021-09-30 78.49 $4.33 18.13
2021-06-30 87.57 $3.95 22.17
2021-03-31 82.04 $3.48 23.58
2020-12-31 87.29 $3.52 24.80
2020-09-30 80.38 $3.09 26.01
2020-06-30 80.73 $3.14 25.71
2020-03-31 76.21 $5.24 14.54
2019-12-31 84.41 $5.05 16.72
2019-09-30 77.47 $5.07 15.28
2019-06-30 81.40 $4.87 16.71
2019-03-31 75.25 $5.27 14.28
2018-12-31 67.16 $5.37 12.51
2018-09-30 67.44 $5.70 11.83
2018-06-30 59.12 $5.89 10.04
2018-03-31 63.28 $3.41 18.56
2017-12-31 63.43 $3.25 19.52
2017-09-30 64.86 $2.81 23.08
2017-06-30 63.06 $2.74 23.01
2017-03-31 56.11 $2.66 21.09
2016-12-31 53.12 $2.80 18.97
2016-09-30 57.59 $2.84 20.28
2016-06-30 60.18 $2.80 21.49
2016-03-31 52.83 $2.80 18.87
2015-12-31 60.46 $7.28 8.30
2015-09-30 64.59 $7.45 8.67
2015-06-30 69.10 $7.99 8.65
2015-03-31 69.29 $8.27 8.38
2014-12-31 63.33 $4.14 15.30
2014-09-30 64.33 $4.35 14.79
2014-06-30 61.87 $3.94 15.70
2014-03-31 58.11 $3.94 14.75
2013-12-31 53.16 $3.72 14.29
2013-09-30 50.73 $3.73 13.60
2013-06-30 46.76 $3.84 12.18
2013-03-31 47.11 $3.92 12.02
2012-12-31 40.33 $3.90 10.34
2012-09-30 39.03 $3.55 11.00
2012-06-30 35.62 $3.55 10.03
2012-03-31 35.31 $3.55 9.95
2011-12-31 34.87 $3.80 9.18
2011-09-30 34.02 $4.26 7.98
2011-06-30 37.27 $4.24 8.79
2011-03-31 33.15 $4.19 7.91
2010-12-31 34.48 $4.28 8.06
2010-09-30 33.73 $4.35 7.75
2010-06-30 28.26 $4.28 6.60
2010-03-31 31.64 $4.11 7.70
2009-12-31 30.71 $3.69 8.32
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $181.123B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Eli Lilly (LLY) United States $297.134B 35.06
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27